Login to Your Account



No immunoglobulin, no problem?

China's Yisheng moves rabies vaccine into Singapore clinical trials

By Cornelia Zou
Staff Writer

Tuesday, March 17, 2015
HONG KONG – A Chinese biotech company has moved its innovative rabies vaccine into human trials in Singapore, with the hope of making therapy less dependent on the assistance of immunoglobulin.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription